RxSight, Inc.
RXST · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $30 | $34 | $38 | $40 |
| % Growth | -9.8% | -11.2% | -5.8% | – |
| Cost of Goods Sold | $6 | $8 | $10 | $11 |
| Gross Profit | $24 | $25 | $28 | $29 |
| % Margin | 79.9% | 74.9% | 74.8% | 71.6% |
| R&D Expenses | $9 | $10 | $10 | $9 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $27 | $29 | $29 | $28 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $36 | $39 | $39 | $37 |
| Operating Income | -$12 | -$14 | -$11 | -$9 |
| % Margin | -40.1% | -41.6% | -28.2% | -21.5% |
| Other Income/Exp. Net | $2 | $2 | $3 | $3 |
| Pre-Tax Income | -$10 | -$12 | -$8 | -$6 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$10 | -$12 | -$8 | -$6 |
| % Margin | -32.4% | -35% | -21.6% | -14.8% |
| EPS | -0.24 | -0.29 | -0.2 | -0.15 |
| % Growth | 17.2% | -45% | -33.3% | – |
| EPS Diluted | -0.24 | -0.29 | -0.2 | -0.15 |
| Weighted Avg Shares Out | 41 | 41 | 41 | 40 |
| Weighted Avg Shares Out Dil | 41 | 41 | 41 | 40 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $2 | $3 | $3 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$9 | -$11 | -$7 | -$5 |
| % Margin | -29.5% | -32.6% | -19.5% | -13.4% |